TOVX supply chain intelligence for Theriva Biologics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| CADL | Candel Therapeutics, Inc. | 72% | prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Modifications or enhancem… |
| CADL | Candel Therapeutics, Inc. | 72% | Reciprocal relationship from CADL graph: Reciprocal relationship from TOVX graph: prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in … |
| CGON | CG Oncology, Inc. | 72% | Reciprocal relationship from CGON graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from CGON graph: Reciprocal relationship from TOVX graph: prescribe legally available drugs f… |
| CGON | CG Oncology, Inc. | 72% | prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Modifications or enhancem… |
| CLDWW | CLDWW | 72% | Reciprocal relationship from CLDWW graph: Reciprocal relationship from TOVX graph: prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in… |
| CLDWW | CLDWW | 72% | prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Modifications or enhancem… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: g process and had to demonstrate analytical comparability to the FDA in order to use Olvi-Vec manufactured by this process in our ongoing Phase 3 PRROC trial.… |
| MCRB | Seres Therapeutics, Inc. | 72% | prescribe legally available drugs for off-label uses, drugs may be marketed only for the approved indications and in accordance with the provisions of the approved labeling. Modifications or enhancem… |
| MCRB | Seres Therapeutics, Inc. | 72% | Reciprocal relationship from MCRB graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from MCRB graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from MCRB g… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| RASAYANA | RASAYANA | 92% | Under the terms of the Rasayana License Agreement, the Company received an upfront payment of Three Hundred Thousand Dollars ($ 300,000 ) from Rasayana on the effective date of the Rasayana License A… |
| GNLX | Genelux Corporation | 72% | Reciprocal relationship from GNLX graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX graph: Reciprocal relationship from TOVX graph: Reciprocal relationship from GNLX g… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| TOVX-DEBT-13069 | Warrants outstanding: 13672173 | 90% | xbrl warrant detail from xbrl 2025-12-31. |
| TOVX-DEBT-13070 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2024-06-30. |
| TOVX-DEBT | Debt stack $3.7M | 90% | Market cache reports total debt of $3.7M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| TOVX-OWNER-IKARIAN-CAPITAL-LLC | Ikarian Capital, LLC | 95% | 13F/ownership overlay lists Ikarian Capital, LLC; shares held 112,076; ownership 0.24%; value $22,672; as of 2025-12-31. |
| TOVX-OWNER-XTX-TOPCO-LTD | Xtx Topco Ltd | 95% | 13F/ownership overlay lists Xtx Topco Ltd; shares held 39,445; ownership 0.09%; value $7,979; as of 2025-12-31. |
| TOVX-OWNER-VANGUARD-GROUP-INC | Vanguard Group Inc | 95% | 13F/ownership overlay lists Vanguard Group Inc; shares held 255,727; ownership 0.56%; value $51,733; as of 2025-12-31. |
| TOVX-OWNER-GEODE-CAPITAL-MANAGEMENT-LLC | Geode Capital Management, LLC | 95% | 13F/ownership overlay lists Geode Capital Management, LLC; shares held 212,087; ownership 0.46%; value $42,905; as of 2025-12-31. |
| TOVX-OWNER-MORGAN-STANLEY | Morgan Stanley | 95% | 13F/ownership overlay lists Morgan Stanley; shares held 200,000; ownership 0.44%; value $40,459; as of 2025-12-31. |
| TOVX-OWNER-UBS-GROUP-AG | UBS Group AG | 95% | 13F/ownership overlay lists UBS Group AG; shares held 191,410; ownership 0.42%; value $38,722; as of 2025-12-31. |
| TOVX-OWNER-STONEX-GROUP-INC | Stonex Group Inc. | 95% | 13F/ownership overlay lists Stonex Group Inc.; shares held 37,217; ownership 0.08%; value $7,528; as of 2025-12-31. |
| TOVX-OWNER-TWO-SIGMA-SECURITIES-LLC | Two Sigma Securities, LLC | 95% | 13F/ownership overlay lists Two Sigma Securities, LLC; shares held 42,893; ownership 0.09%; value $8,677; as of 2025-12-31. |
| TOVX-OWNER-DRW-SECURITIES-LLC | DRW Securities, LLC | 95% | 13F/ownership overlay lists DRW Securities, LLC; shares held 41,745; ownership 0.09%; value $8,445; as of 2025-12-31. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| CGON | CG Oncology, Inc. | 100.00 | 1 | ['supplier'] |
| GNLX | Genelux Corporation | 100.00 | 1 | ['customer', 'supplier'] |
| CLDWW | Calidi Biotherapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| CADL | Candel Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| MCRB | Seres Therapeutics, Inc. | 100.00 | 1 | ['supplier'] |
| BMY | Bristol-Myers Squibb Company | 50.00 | 2 | |
| BMYMP | Bristol-Myers Squibb Co | 50.00 | 2 | |
| ONCY | Oncolytics Biotech Inc. | 50.00 | 2 | |
| ENLV | Enlivex Ltd. | 50.00 | 2 | |
| TRIN | Trinity Capital Inc. | 50.00 | 2 | |
| MYGN | Myriad Genetics, Inc. | 50.00 | 2 | |
| REPL | Replimune Group, Inc. | 50.00 | 2 | |
| IOVA | Iovance Biotherapeutics, Inc. | 50.00 | 2 | |
| JNJ | Johnson & Johnson | 50.00 | 2 | |
| LLY | Eli Lilly and Company | 50.00 | 2 | |
| BDRX | Biodexa Pharmaceuticals Plc | 50.00 | 2 | |
| OCSL | Oaktree Specialty Lending Corporation | 50.00 | 2 | |
| CELG-RI | BRISTOL MYERS SQUIBB CO | 50.00 | 2 | |
| HTGC | Hercules Capital, Inc. | 50.00 | 2 | |
| REGN | Regeneron Pharmaceuticals, Inc. | 50.00 | 2 |